Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
21.71
-0.01 (-0.05%)
At close: Nov 26, 2025, 4:00 PM EST
21.50
-0.21 (-0.97%)
After-hours: Nov 26, 2025, 5:13 PM EST
Innoviva Revenue
Innoviva had revenue of $107.80M in the quarter ending September 30, 2025, with 20.44% growth. This brings the company's revenue in the last twelve months to $388.52M, up 10.14% year-over-year. In the year 2024, Innoviva had annual revenue of $358.71M with 15.54% growth.
Revenue (ttm)
$388.52M
Revenue Growth
+10.14%
P/S Ratio
3.59
Revenue / Employee
$3,059,220
Employees
127
Market Cap
1.62B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 358.71M | 48.25M | 15.54% |
| Dec 31, 2023 | 310.46M | -20.88M | -6.30% |
| Dec 31, 2022 | 331.34M | -60.53M | -15.45% |
| Dec 31, 2021 | 391.87M | 55.07M | 16.35% |
| Dec 31, 2020 | 336.79M | 75.78M | 29.03% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
INVA News
- 2 days ago - Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference - Business Wire
- 22 days ago - Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress - Business Wire
- 5 weeks ago - Antheia Appoints Eric d'Esparbes as Chief Financial Officer - PRNewsWire
- 5 weeks ago - Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025 - Business Wire
- 7 weeks ago - Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025 - Business Wire
- 3 months ago - Innoviva, Inc. (INVA) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 3 months ago - Innoviva to Participate in Upcoming Investor Conferences - Business Wire
- 3 months ago - Innoviva Specialty Therapeutics' Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award - Business Wire